Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli Lilly intensifies. ・The report marks CEO Mike Doustdar’s first since ...

Shares of Hims & Hers Health ($HIMS) rallied in pre-market hours on Tuesday after management said it’s in discussions with ...

Novo Nordisk NVO is scheduled to report its third-quarter 2025 results before the opening bell on Nov. 5, 2025. The Zacks ...

Novo Nordisk’s sharp decline may have opened the door for a massive rebound here’s why investors are watching its ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Plus, inside the super secretive intelligence firm Black Cube and Pfizer takes no prisoners in its fight to buy Metsera ...

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United ...

Hims & Hers said that the discussions with Novo Nordisk (DK:NOVO.B) are ongoing, that "no definitive agreement" has been reached, and that the two companies may not reach one. Nonetheless, Hims & Hers ...

Hims and Hers Health missed Wall Street estimates for third-quarter profit on Monday, hit by increased product costs and ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Pfizer today announced that it has filed a second lawsuit against Metsera, its controlling stockholders, and Novo Nordisk in the US District Court for the District of Delaware.